Quick Answer
UroGen Pharma Ltd. reported Net Income Loss of -$153.49 million for the year ending 2025.
- UroGen Pharma Ltd. showed a decrease of -21.0% in Net Income Loss from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$3.42 million | Q2 2017: -$6.20 million | Q3 2017: -$298.0 thousand | Q4 2017: -$10.09 million | Q1 2018: -$13.38 million | Q2 2018: -$18.03 million | Q3 2018: -$20.53 million | Q4 2018: -$23.72 million | Q1 2019: -$21.44 million | Q2 2019: -$22.48 million | Q3 2019: -$22.25 million | Q4 2019: -$38.97 million | Q1 2020: -$37.79 million | Q2 2020: -$31.35 million | Q3 2020: -$28.82 million | Q1 2021: -$25.94 million | Q2 2021: -$26.22 million | Q3 2021: -$30.21 million | Q1 2022: -$28.39 million | Q2 2022: -$26.69 million | Q3 2022: -$25.83 million | Q1 2023: -$30.21 million | Q2 2023: -$24.14 million | Q3 2023: -$21.88 million | Q4 2023: -$26.02 million | Q1 2024: -$32.29 million | Q2 2024: -$33.40 million | Q3 2024: -$23.67 million | Q4 2024: -$37.51 million | Q1 2025: -$43.84 million | Q2 2025: -$49.94 million | Q3 2025: -$33.35 million.
- Over the full 11 years of available data (2015 to 2025), UroGen Pharma Ltd.'s Net Income Loss has declined by 1,109.7%.
- Historical annual values: Fiscal year 2025: -$153.49 million | Fiscal year 2024: -$126.87 million | Fiscal year 2023: -$102.24 million | Fiscal year 2022: -$109.78 million | Fiscal year 2021: -$110.82 million | Fiscal year 2020: -$128.48 million | Fiscal year 2019: -$105.15 million | Fiscal year 2018: -$75.66 million | Fiscal year 2017: -$20.00 million | Fiscal year 2016: -$1.94 million | Fiscal year 2015: -$12.69 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: